BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Microbiome Times Magazine - ECPv6.11.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Microbiome Times Magazine
X-ORIGINAL-URL:https://www.microbiometimes.com
X-WR-CALDESC:Events for Microbiome Times Magazine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Athens
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200608
DTEND;VALUE=DATE:20200611
DTSTAMP:20260414T091841
CREATED:20200227T212008Z
LAST-MODIFIED:20200227T212008Z
UID:3801-1591574400-1591833599@www.microbiometimes.com
SUMMARY:The Microbiome Movement – Drug Development Summit Boston
DESCRIPTION:The Microbiome Movement – Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical\, biotech and academic community pursue the causal role of the human microbiome in disease\, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs. \nWith 70+ world class speakers\, 3 days of unrivalled content\, 2 deep dive workshops and 1 pre-conference oncology day\, attendance will give you access to: \n\nMore Clinical Case-Studies for Microbiome-Based Therapeutics\nWith industry attention on demonstrating clinical efficacy and progress through human trials\, listen to newly published clinical case-studies from Seres Therapeutics\, Finch Therapeutics\, Rebiotix\, as well as clinician perspectives from Brigham & Women’s Hospital\, Mayo Clinic and OpenBiome to give you expert insights from the trailblazers in the industry\nNew Insights on Microbiome Biomarkers\, Diagnostics and Drug Metabolism\nAs the microbiome continues to demonstrate itself as a major factor in personalized medicine\, this year’s discussion will continue to shine the spotlight on microbiome biomarkers as a tool to accurately diagnose and treat disease with case-studies from the Crohn’s & Colitis Foundation\, DayTwo\, Viome\, Merck ESC and many more to share the most exciting area in microbiome research\nThe Next Generation of Microbiome-Targeting Modalities & Drug Discovery Platforms\nWith progress developing in microbial-derived small molecules\, engineered microbes and subtractive platforms\, hear from Kaleido Biosciences\, Enterome\, Novome Biotechnologies\, BiomX and many more who continue to demonstrate new findings in therapeutic options outside of Live Biotherapeutics\n\nIf you are\, or would like to be\, a player in the microbiome arena\, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics\, biomarkers and diagnostics\, but also to make long-lasting connections that will accelerate your microbiome developments forward\, and help translate this promising science into a reality for patients.
URL:https://www.microbiometimes.com/event/the-microbiome-movement-drug-development-summit-boston/
LOCATION:Boston\, MA\, United States
ATTACH;FMTTYPE=image/png:https://www.microbiometimes.com/wp-content/uploads/2020/02/MM_Drug-Development-USA-2019-1-1.png
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR